Published in Oncol Rep on December 01, 2007
Genome profiling of ovarian adenocarcinomas using pangenomic BACs microarray comparative genomic hybridization. Mol Cytogenet (2008) 0.89
The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle. Front Oncol (2015) 0.81
Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS One (2011) 0.78
Decorin is a part of the ovarian extracellular matrix in primates and may act as a signaling molecule. Hum Reprod (2012) 0.78
Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression. Tumour Biol (2016) 0.75
A conditional knockout resource for the genome-wide study of mouse gene function. Nature (2011) 9.93
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 3.26
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2013) 3.15
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome (2012) 2.65
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res (2008) 2.23
Is there a role for pelvic lymph node debulking in advanced cervical cancer? Gynecol Oncol (2002) 2.23
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol (2011) 2.19
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer (2008) 2.13
Dual RMCE for efficient re-engineering of mouse mutant alleles. Nat Methods (2010) 2.05
Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol (2005) 1.98
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol (2007) 1.89
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res (2007) 1.80
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol (2010) 1.64
The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer (2009) 1.60
Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol (2002) 1.59
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53
Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother (2012) 1.52
Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol (2012) 1.49
Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst (2012) 1.48
Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer (2007) 1.45
Sentinel lymph node in vulvar cancer. Cancer (2007) 1.44
Sentinel lymph nodes. Cancer (2003) 1.38
A scalable pipeline for highly effective genetic modification of a malaria parasite. Nat Methods (2011) 1.31
High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia (2005) 1.22
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst (2010) 1.21
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol (2008) 1.19
Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev (2012) 1.17
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol (2006) 1.14
Fertility-sparing options for early stage cervical cancer. Gynecol Oncol (2010) 1.11
Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy. Gynecol Oncol (2003) 1.08
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08
Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res (2002) 1.04
Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev (2006) 1.03
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. Nat Clin Pract Oncol (2007) 0.99
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol (2013) 0.98
Pregnancy outcomes in patients after radical trachelectomy. Am J Obstet Gynecol (2003) 0.98
Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med (2007) 0.95
Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys (2005) 0.94
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol (2010) 0.92
Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma. Cancer (2003) 0.92
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2011) 0.92
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol (2005) 0.91
Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia (2008) 0.91
Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int (2007) 0.91
Adenocarcinoma involving the uterine cervix: magnetic resonance imaging findings in tumours of endometrial, compared with cervical, origin. Can Assoc Radiol J (2006) 0.91
Feasibility of same-day discharge after laparoscopic surgery in gynecologic oncology. Gynecol Oncol (2011) 0.90
Adipogenesis: new insights into brown adipose tissue differentiation. J Mol Endocrinol (2013) 0.90
The interaction between ER and NFκB in resistance to endocrine therapy. Breast Cancer Res (2012) 0.90
Role of sentinel lymph node biopsy in cervical cancer: pro. Int J Gynecol Cancer (2010) 0.89
Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia. BMC Genomics (2006) 0.89
Height, weight, BMI and ovarian cancer survival. Gynecol Oncol (2012) 0.88
Initial evaluation and referral guidelines for management of pelvic/ovarian masses. J Obstet Gynaecol Can (2009) 0.88
Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience. Biopreserv Biobank (2013) 0.88
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol (2014) 0.87
Teaching cervical cancer surgery in low- or middle-resource countries. Int J Gynecol Cancer (2010) 0.87
Influenza-like illness in hospitalized pregnant and postpartum women during the 2009-2010 H1N1 pandemic. Obstet Gynecol (2011) 0.87
Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes. J Med Genet (2011) 0.86
Surgery for early stage cervical cancer: how radical should it be? Gynecol Oncol (2013) 0.86
Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res (2005) 0.86
Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med (2004) 0.85
Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer (2004) 0.85
Breast and ovarian cancer: the forgotten paternal contribution. J Genet Couns (2011) 0.85
Electrochromatography in poly(dimethyl)siloxane microchips using organic monolithic stationary phases. Electrophoresis (2007) 0.84
The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology (2011) 0.84
A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010. World J Surg Oncol (2013) 0.84
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol Oncol (2009) 0.83
Association of the Duration of Active Pushing With Obstetric Outcomes. Obstet Gynecol (2016) 0.83
Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study. Tumour Biol (2006) 0.83
Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles. Gynecol Oncol (2012) 0.83
Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1. Gynecol Oncol (2008) 0.83
MDI Biological Laboratory Arsenic Summit: Approaches to Limiting Human Exposure to Arsenic. Curr Environ Health Rep (2015) 0.81
Characterization of trisomy 8 in pediatric undifferentiated sarcomas using advanced molecular cytogenetic techniques. Cancer Genet Cytogenet (2007) 0.81
Vaginal vault dehiscence and increased use of vaginal vault brachytherapy: what are the implications? Int J Gynecol Cancer (2012) 0.81
Role of adjuvant radiotherapy in granulosa cell tumors of the ovary. Int J Radiat Oncol Biol Phys (2010) 0.81
Breast and ovarian cancer: Y do we forget about dad? Lancet Oncol (2010) 0.81
Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecol Oncol (2010) 0.81
Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer (2015) 0.81
Intraoperative consultation in gynecologic pathology: a 6-year audit at a tertiary care medical center. Int J Gynecol Cancer (2009) 0.81
An organizational guideline for gynecologic oncology services. Int J Gynecol Cancer (2015) 0.80
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol (2009) 0.80